DuPont Acquires Danisco in $6.3B Deal

Quick Links In the News Analysis & Insight Webinars App Notes   Online Exclusives More at GEN Subscriber Tools   GEN NEWS HIGHLIGHTS Monday, January 10, 2011 View email in a browser           Forward to a colleague DuPont Acquires Danisco in $6.3B Deal Acquisition further strengthens DuPont's position in the industrial biotechnology field. GSK Pays Epizyme $20M Up Front as Part of Histone Methyltransferase Inhibitor Deal Development of HMT therapeutics against targets for cancer and other diseases is primary objective. FDA Approves ProStrakan's Abstral for Breakthrough Cancer Pain Company claims transmucosal product already has 24% share of fast-acting fentanyl market in major EU markets. Civitas Raises $20M for Parkinson Disease Program Company is developing a dry powder pulmonary delivery platform. Biocartis Signs Assay Deal for Its MDx Platform with Janssen Pharmaceutica J&J subsidiary will develop neurological disease and infectious viral disease assays. AMT Secures Option to License Sanfilippo B Gene Therapy from Institut Pasteur-Led Consortium AMT may acquire full commercial rights to product at end of Phase I/II trial. Celtic Therapeutics Acquires and Licenses Rights to Resolvyx' RX-10045 Agreement will allow further development of Resolvin-based therapy. Ardea Biosciences Gets $15M from Bayer Upon Start of Phase II Trial with Liver Cancer Compound Ardea has received $50 million so far from its deal with Bayer, with potential to earn another $357 million. BMS and Pharmasset to Combine HCV Candidates in Proof-of-Concept Study Trial will fuse BMS NS5A replication inhibitor with Pharmasset's NS5B polymerase blocker. LabCorp to Market On-Q-ity's CTC Platform for Cancer Drug Discovery and Development Firms claim microfluidics-based system will provide early indicator of drug response. You can view more news broken down into over 90 categories and updated daily. Analysis & Insight What Will Succeed Lipitor as the Next Blockbuster Cholesterol-Lowering Drug? CEPT inhibitors are vying to take over from statins, but one major failure hovers ominously.     More A&Is Webinars Available on Demand: Original Broadcast Date - December 16, 2010 Simplifying Targeted Protein Quantification with Mass Spec: The SRM Atlas and Multiplexed MRM Protein Assays Sponsored by: Agilent Technologies In Case You Missed It: If you couldn't attend a previous webinar, be sure to check out our On-Demand Archives. Application Note Library Mapping Protein Stability Using Automated CD Outstanding Sensitivity for Confident Label-Free Interaction Analysis Analysis of an O-linked Glycopeptide Using Multiple Stage Mass Spectrometry Reliability of Size Exclusion Chromatography Measurements on the ACQUITY UPLC H-Class Bio System Reproducible Dispensing of Live Cells with the Thermo Scientific Multidrop Combi Reagent Dispenser More App Notes Online Exclusives BLOGBIOTECH: Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs and Devices    More Blogs POLL: Do you think the Green Movement goes too far in its opposition of many new technologies?    More Polls More at GEN GEN Subscriber Tools Subscription Center l Unsubscribe l Update Your Profile l About GEN IMPORTANT! Make sure you receive your chosen GEN e-Newsletters. Add update@genengnews.com to your Address Book or Safe Senders List. It's easy! Click HERE for instructions. Contact Us For: Advertising   Editorial   Business and Partnership Opportunities This email was sent by: Genetic Engineering & Biotechnology News 140 Huguenot St., New Rochelle, NY 10801, USA